Although the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib have shown dramatic effects against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper EGFR-T790M mutation, Met amplification and HGF overexpression, thereafter relapsing. Thus, it is urgent to develop novel agents to overcome EGFR-TKI resistance. We have tested 
Introduction
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have shown marked therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations, such as exon 19 deletions and L858R point mutations (1) . Almost all tumors, however, acquire resistance to EGFR-TKIs after varying periods of time. Among the molecular mechanisms of this acquired resistance to EGFR-TKIs are gatekeeper mutations in EGFR (i.e. a T790M second mutation) and bypass signaling caused by Met amplification or hepatocyte growth factor (HGF) overexpression (2) (3) (4) (5) . In addition, PIK3CA mutations and transformation to SCLC have been found to contribute to EGFR-TKI resistance in a subpopulation of tumors (6) . All of these alterations have been detected in clinical specimens from EGFR mutant lung cancer patients who became resistant to EGFR-TKIs (6, 7), indicating the urgent need to develop effective therapies for these patients. resistance mutation. In preclinical models, the combination of a Met-TKI and an EGFR-TKI was shown effective in overcoming resistance caused by Met amplification (11). Among the Met-TKIs being evaluated in clinical trials is crizotinib, which also inhibits ALK and has been approved by the U.S. FDA to treat patients with EML4-ALK lung cancer (12). In addition, a phase 1 clinical trial of E7050, a dual inhibitor of Met and VEGFR-2, was recently completed (13) .
Although the combination of a mutant selective EGFR-TKI and a Met-TKI can theoretically overcome the resistance caused by all three mechanisms, this effect has not yet been assessed. We therefore analyzed whether the combination of the mutant selective EGFR-TKI WZ4002 and the Met-TKI E7050 could inhibit the growth of cells with the three types of EGFR-TKI resistance mechanisms.
WZ4002 and E7050 are shown in Fig. 1C .
HGF gene transfection
One day before transfection, aliquots of 1×10 5 PC-9 cells in 1 ml of antibiotic-free medium were added to each well of a 6-well plate. The cells were subsequently transfected with full-length HGF cDNA cloned into the BCMGSneo expression vector (16) using Lipofectamine 2000, in accordance with the manufacturer's instructions. After incubation for 24 h, the cells were washed with PBS and incubated for an additional 72 h in antibiotic-containing medium, followed by selection in G418 sulfate (Calbiochem, La Jolla, CA). After limiting dilution, an HGF-producing cell line, PC-9/HGF, was established.
HGF production
Cells (1×10 5 ) were cultured in RPMI1640 medium containing 10% FBS for 24 h, washed with PBS and incubated for 24 h in 1 ml of RPMI1640 medium containing 10%
FBS. The culture medium was harvested and centrifuged, and the supernatant was samples were assayed in duplicate. Color intensity was measured at 450 nm using a spectrophotometric plate reader. HGF concentrations were determined by comparison with a standard curve. The limit of detection was 30 pg/ml.
Cell proliferation assay
Cell growth was measured using the MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium] dye reduction method (17). Tumor cells (2×10 3 cells/100 L/well) were plated into each well of 96-well plates in RPMI1640 medium containing 10% FBS. After incubation for 24 h, various reagents were added to each well, and the plates were incubated for an additional 72 h. To each well was added 50 μL of MTT (2 mg/ml; Sigma, St. Louis, MO), and incubation was continued for a further 2 h. The media containing MTT solution were removed, and the dark blue crystals in each well were dissolved in 100 μL DMSO. The absorbance of each well at 570 nm was measured with a microplate reader, with the percentage growth shown relative to untreated controls.
Western blot analysis
Culture cells and subcutaneous tumors were lysed in cell lysis buffer containing phosphatase inhibitor cocktail and proteinase inhibitor cocktail (Sigma), and the protein concentrations were determined using a BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL). Total protein (20~40 μg) was subjected to SDS-PAGE (Bio-Rad, Hercules, CA) under reducing conditions and transferred to PVDF membranes (Bio-Rad). The membranes were blocked with TBS containing 0.05% Tween-20 and either 5% skim milk or 5% BSA and incubated with antibodies to phospho-Met (Y1234/Y1235) (D26), phospho-EGFR (Y1068), ErbB3 (1B2), phospho-ErbB3 (Tyr1289) (21D3), Gab1, phospho-Gab1 (Y627)(C32H2), Akt, and phospho-Akt (Ser473) (Cell Signaling Technology, Beverly, MA); Met (C-28) (Santa Cruz Biotechnology Inc, Santa Cruz, CA); and phospho-Erk1/2 (T202/Y204), Erk1/2 and EGFR (R&D Systems, Minneapolis, MN).
After washing 3 times, the membranes were incubated for 1 h at room temperature with species-specific horseradish peroxidase-conjugated secondary antibodies.
Immunoreactive bands were visualized using SuperSignal West Dura Extended Duration Substrate Enhanced Chemiluminescent Substrate (Pierce Biotechnology).
Each experiment was performed at least 3 times independently. peroxidase complex (ABC) using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA). The DAB (3,3'-diaminobenzidine tetrahydrochloride) Liquid System (Dako Cytomation) was used to detect immunostaining.
Statistical analysis
Between group differences were analyzed by one-way ANOVA. All statistical analyses were performed using GraphPad Prism Ver. 4.01 (GraphPad Software, Inc., San Diego, CA), with P < 0.05 considered statistically significant. 
Results

HGF triggers resistance to mutant selective EGFR-TKI WZ4002
PC-9 cells, a human lung cancer cell line with an EGFR exon 19 deletion and highly sensitive to gefitinib and erlotinib (18), were transfected with a human HGF gene, yielding the human HGF overexpressing clones (Fig. 1A) , PC-9/HGF#4 and PC-9/HGF#5. Although PC-9/Vec cells, a vector control, were sensitive to EGFR-TKIs, such as erlotinib and WZ4002 ( Fig. 2A, Supplementary Fig. S1A ), PC-9/HGF cells were resistant to both ( Fig. 2B and C, Supplementary Fig. S1B , C).
E7050 is an orally bioavailable small molecule that inhibits Met and VEGFR-2 activity (13) . Although E7050 alone did not affect the viability of PC-9/Vec and PC-9/HGF cells ( Fig. 2A , B, C), E7050 sensitized PC-9/HGF cells to WZ4002 (Fig. 2B, C) . In assessing the effects of HGF overexpression on tumor cell migration, we found that HGF overexpression enhanced the migration activity of PC-9 cells, whereas WZ4002 had no effect against the motility of PC-9/Vec and PC-9/HGF#5 cells. In contrast E7050 inhibited the migration of PC-9/HGF#5 cells induced by HGF overexpression (Supplementary Fig. S2 ).
In exploring signal transduction status by western blotting, we found that WZ4002 inhibited EGFR phosphorylation in PC-9/Vec cells, suppressing the phosphorylation of Table S1 ). This HGF-triggered resistance was totally abrogated by E7050 (Fig. 3B , Supplementary Table S1 ). Western blot analyses showed that WZ4002 inhibited EGFR phosphorylation, thereby suppressing the phosphorylation of Akt and Erk. HGF did not restore EGFR phosphorylation, but did restore and enhance Akt and Erk phosphorylation ( 
Combined treatment with WZ4002 and E7050 overcomes various resistance mechanisms in vivo
We assessed the efficacy of the combination of WZ4002 and E7050 in three completely inhibited the growth of PC-9/Vec tumors, whereas treatment with E7050 did not (Fig. 4A) . Treatment with either agent alone slightly suppressed the growth of PC-9/HGF#5 tumors (Fig. 4B) . Importantly, the combination of WZ4002 and E7050 reduced the size of PC-9/HGF#5 tumors (Fig. 4B) . These results suggest that HGF can induce resistance to WZ4002 in vivo and that this resistance can be overcome by E7050.
In the second model, the growth of tumors induced by H1975 cells, which carry a T790M second mutation, was inhibited by WZ4002 (Fig. 4C ), but not erlotinib ( Supplementary Fig. S2F ). E7050 also slightly inhibited the growth of H1975 tumors, whereas the combination of E7050 and WZ4002 did not further inhibit tumor growth in this model. These results suggest that WZ4002 monotherapy may be sufficient to overcome erlotinib resistance induced by the T790M second mutation, as reported previously (10).
In the third model, in which resistance was induced by Met amplification, monotherapy with either WZ4002 or E7050 partially inhibited the growth of HCC827ER tumors (Fig. 4D) , consistent with our in vitro findings (Fig. 3C) , whereas combined treatment markedly reduced tumor size (Fig. 4D ). During treatment with WZ4002 or E7050, either alone or in combination, there were no macroscopic changes or evidence Fig. S5 ).
Collectively, these in vivo data suggest that the combination of a mutant selective EGFR-TKI and a Met-TKI may overcome erlotinib resistance caused by a T790M second mutation, Met amplification or HGF overexpression.
Therapeutic effects of WZ4002 and E7050 are associated with the inhibition of EGFR and Met phosphorylation in vivo
To evaluate the effects of combined treatment with WZ4002 and E7050 on resistance caused by Met amplification and HGF overexpression, we analyzed the phosphorylation status of target molecules in the tumors. Immunohistochemical analysis showed that Met and EGFR were phosphorylated in the plasma membranes of HCC827ER cells (Fig.   5A ). Treatment with WZ4002 or E7050 inhibited the phosphorylation of EGFR or Met, respectively, whereas combined treatment inhibited the phosphorylation both (Fig. 5A) , a result confirmed by Western blot analyses (Fig. 5B) . Western blot analyses of downstream signals showed that combined treatment with WZ4002 and E7050 showed greater inhibition of Erk and Akt phosphorylation than observed in control cells or cells treated with each agent alone, even in vivo (Fig. 5B) . We observed similar findings in PC-9/HGF#5 tumors (Fig. 5C ). These results indicate that the anti-tumor effects of 
WZ4002 and E7050 are associated with the inhibition of both EGFR and Met phosphorylation, even in vivo.
We further evaluated tumor cell proliferation by Ki-67 staining. We observed active cell proliferation in HCC827ER tumors, with a 52% proliferation index (Fig. 6A, B) . Supplementary Fig. S6 ), suggesting that combination treatment has a cytostatic effect.
Since E7050 can inhibit VEGFR-2, we also evaluated the effects of E7050 on angiogenesis. CD31 staining showed that E7050, with or without WZ4002, significantly decreased the vascular density of HCC827ER tumors. The ability of E7050 to inhibit VEGFR-2 also suggests a link between its anti-tumor and anti-angiogenesis effects. 
These findings also suggest that the combination of the mutant selective EGFR-TKI inhibitor WZ4002 and the Met-TKI inhibitor E7050 can overcome erlotinib resistance resulting from mutant EGFR, Met inhibition and VEGFR-2 inhibition. 
Discussion
Recent prospective studies have demonstrated that the EGFR-TKIs gefitinib and erlotinib are associated with a high response rate and prolong progression free survival in patients with EGFR mutant lung cancer (1, 21) . Responders to these agents, however, later relapse after acquiring EGFR-TKI resistance, making it urgent to develop novel therapeutic agents that can overcome acquired resistance to EGFR-TKIs. To our knowledge, this study is the first to show that the combination of a mutant selective EGFR-TKI and a Met-TKI is effective against tumor cell lines refractory to erlotinib by three different mechanisms: an EGFR gatekeeper T790M mutation, Met amplification and HGF overexpression. This may be due, at least in part, to the low selectivity of this class of compounds to wild type and mutant EGFR. WZ4002 is a mutant selective EGFR-TKI with high activity against EGFR with both sensitive (e.g. exon 19 deletion and L858R) and resistant (T790M) mutations. Nevertheless, since HGF overexpression was frequently observed in tumors with the gatekeeper T790M mutation (7, 27), monotherapy with a mutant selective EGFR-TKI may not be sufficient to inhibit the growth of tumors with acquired resistance to gefitinib and erlotinib. Our findings suggest that the combination of a Met-TKI and a mutant selective EGFR-TKI may be effective in controlling these resistant tumors. (28) . When combined with WZ4002, however, the orally active Met-TKI E7050 efficiently abrogated erlotinib resistance due to Met amplification.
E7050 is now being evaluated in clinical trials.
Recent studies have revealed molecular mechanisms of resistance to molecularly targeted agents (29), and many candidate drugs that could overcome this resistance have been developed (30) . A biopsy following the development of resistance may result in the accurate molecular diagnosis of resistance mechanisms and the use of appropriate agents (6) . Difficulties in molecular diagnosis may arise, however, when multiple lesions progress after becoming resistant. In some patients, the recurrent tumors may be caused by the same resistance mechanism, whereas, in other patients, these tumors may be caused by several mechanisms (7, 14) ; thus, re-biopsy of a single lesion may be insufficient for an accurate molecular diagnosis. Since acquired resistance to EGFR-TKIs in most patients with EGFR mutant lung cancer is likely 
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